Taxanes as first-line therapy for advanced non-small cell lung cancer: A systematic review and practice guideline

Lung Cancer

Volumn 50, Issue 3, 2005, Pages 355-374

  Chu, Quincy ^a   Vincent, Mark ^b   Logan, Diane ^b   Mackay, Jean A ^c   Evans, William K ^c   Alam, Yasmin ^d   Bradish, Grace ^d   Brundage, Michael ^d   Cheng, Susanna ^d   Dar, A R ^d   Darling, Gail ^d   De Metz, Catherine ^d   Dingle, Brian ^d   Dixon, Peter ^d   Ellis, Peter ^d   Falkson, Conrad ^d   Feld, Ronald ^d   Goss, Glen ^d   Graham, Ian ^d   Gregg, Richard ^d   Haynes, Adam ^d   Kiteley, Cathy ^d   Kocha, Walter ^d   Kotalik, Jaro ^d   Laurie, Scott ^d   MacRae, Robert ^d   Malthaner, Richard ^d   Maziak, Donna ^d   Meng, Joanne ^d   Miller, John ^d   Noble, Jonathan ^d   Okawara, Gordon ^d   Shepherd, Frances ^d   Stewart, David ^d   Yee, Chung Ung ^d   Walde, David ^d   Yu, Edward ^d   more..

^a CROSS CANCER INSTITUTE   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d McMaster University ^*

Author keywords

Chemotherapy; Docetaxel; Non small cell lung cancer; Paclitaxel; Practice guideline; Treatment guideline

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; TENIPOSIDE; VINBLASTINE; VINDESINE;

ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; FEBRILE NEUTROPENIA; HAIR LOSS; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; META ANALYSIS; MYALGIA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL TRIALS, PHASE III; HUMANS; LUNG NEOPLASMS; META-ANALYSIS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; TAXOIDS;

EID: 33644530674     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2005.06.010     Document Type: Review

References (69)

1. D.M. Parkin Global cancer statistics in the year 2000 Lancet Oncol 2 2001 533 543
2. C.R.J. Thomas, T.E. Williams, E. Cobos, and A.T. Turrisi Lung cancer R.E.J. Lenhard R.T. Osteen T. Gansler Clinical oncology 2001 The American Cancer Society Atlanta, GA 269 295
3. K. Gelmon The taxoids: paclitaxel and docetaxel Lancet 344 1994 1267 1272
4. F.A. Shepherd, J. Dancey, R. Ramlau, K. Mattson, R. Gralla, and M. O'Rourke Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2000 2095 2103
5. G.P. Browman, M.N. Levine, E.A. Mohide, R.S.A. Hayward, K.I. Pritchard, and A. Gafni The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation J Clin Oncol 13 1995 502 512
6. National Institute of Clinical Excellence. Technology appraisal guidance - No. 26. Guidance on the use of docetaxel, paclitaxel, gemcitabine, and vinorelbine for the treatment of non-small cell lung cancer. NICE website, 2001 [cited 12 December 2001]. Available from: http://www.nice.org.uk/Docref.asp?d= 17535.
7. D.G. Pfister, D.H. Johnson, C.G. Azzoli, W. Sause, T.J. Smith, and S. Baker American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 J Clin Oncol 22 2004 330 353
8. M.A. Socinski, D.E. Morris, G.A. Masters, and R. Lilenbaum Chemotherapeutic management of stage IV non-small cell lung cancer Chest 123 Suppl. 1 2003 226S 243S
9. M. Ranson, N. Davidson, M. Nicolson, S. Falk, J. Carmichael, and P. Lopez Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer J Natl Cancer Inst 92 2000 1074 1080
10. P. Comella, G. Frasci, P. Carnicelli, B. Massidda, F. Buzzi, and G. Filippelli Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients Br J Cancer 91 2004 489 497
11. R.C. Lilenbaum, J.E. Herndon, M.A. List, C. Desch, D.M. Watson, and A.A. Miller Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730) J Clin Oncol 23 2005 190 196
12. C.P. Belani, R.B. Natale, J.S. Lee, M. Socinski, F. Robert, and D. Waterhouse Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 17 1998 455a [abstract 1751]
13. G. Giaccone, T.A.W. Splinter, C. Debruyne, G.S. Kho, P. Lianes, and N. van Zandwijk Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European organization for research and treatment of cancer lung cancer cooperative group J Clin Oncol 16 1998 2133 2141
14. T.E. Ciuleanu, C. Cebotaru, I. Radulescu, N. Todor, and N. Ghilezan Taxol and cisplatin (TP) versus etoposide cisplatin (EP) in advanced non-small cell lung cancer (NSCLC) Eur J Cancer 35 Suppl. 4 1999 251 [abstract 998]
15. P. Bonomi, K. Kim, D. Fairclough, D. Cella, J. Kugler, and E. Rowinsky Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an eastern cooperative oncology group trial J Clin Oncol 18 2000 623 631
16. U. Gatzemeier, J. von Pawel, M. Gottfried, G.P.M. ten Velde, K. Mattson, and F. DeMarinis Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer J Clin Oncol 18 2000 3390 3399
17. K. Kelly, J. Crowley, P.A.J. Bunn, C.A. Presant, P.K. Grevstad, and C.M. Moinpour Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a southwest oncology group trial J Clin Oncol 19 2001 3210 3218
18. R. Rosell, U. Gatzemeier, D.C. Betticher, U. Keppler, H.N. Macha, and R. Pirker Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial Ann Oncol 13 2002 1539 1549
19. G.V. Scagliotti, F. De Marinis, M. Rinaldi, L. Crino, C. Gridelli, and S. Ricci Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer J Clin Oncol 20 2002 4285 4291
20. J.H. Schiller, D. Harrington, C.P. Belani, C. Langer, A. Sandler, and J. Krook Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
21. E.F. Smit, J.P. van Meerbeeck, P. Lianes, C. Debruyne, C. Legrand, and F. Schramel Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European organization for research and treatment of cancer lung cancer group - EORTC 08975 J Clin Oncol 21 2003 3909 3917
22. Y.M. Chen, R.P. Perng, J.F. Shih, Y.C. Lee, C.S. Lee, and C.M. Tsai A randomised phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated Br J Cancer 90 2004 359 365
23. Kubota K, Nishiwaki Y, Ohashi Y, Saijo N, Ohe Y, Tamura T, et al. The four-arm cooperative study (FACS) for advanced non-small-cell lung cancer (NSCLC). J Clin Oncol ASCO Annu Meeting Proc (Post-Meeting Edition) 2004;22(July 15 Suppl. 14S):A7006 [abstract].
24. Kubota K, Nishiwaki Y, Ohashi Y, Saijo N, Ohe Y, Tamura T, et al. The four-arm cooperative study (FACS) for advanced non-small-cell lung cancer (NSCLC) [ASCO slide presentation]. ASCO website. 2004 [cited 2 September 2004]. Available from: http://www.asco.org/ac/1,1003,_12-002511-00_18-0026-00_19- 0010366,00.asp.
25. W.J. Tester, P. Stephenson, C.J. Langer, J.H. Schiller, and D.H. Johnson Rapoport BL. ECOG 1599: randomized phase II study of paclitaxel/carboplatin or gemcitabine/cisplatin in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 23 2004 [abstract 7055]
26. Y.M. Chen, R.P. Perng, Y.C. Lee, J.F. Shih, C.S. Lee, and C.M. Tsai Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated Ann Oncol 13 2002 108 115
27. P. Kosmidis, N. Mylonakis, C. Nicolaides, C. Kalophonos, E. Samantas, and J. Boukovinas Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: a phase III randomized trial J Clin Oncol 20 2002 3578 3585
28. G.P. Stathopoulos, M. Veslemes, N. Georgatou, D. Antoniou, P. Giamboudakis, and K. Katis Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial Ann Oncol 15 2004 1048 1055
29. R.C. Lilenbaum, C.S. Chen, T. Chidiac, P.O. Schwarzenberger, M. Thant, and M. Versola Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer Ann Oncol 16 2005 97 101
30. M. Wiesenfield, R. Marks, J. Grill, J. Sloan, H. Tazelaar, and T. Carroll A randomized phase II study of topotecan (TOPA) and cisplatin (CDDP) with filgrastim (G-CSF) versus topotecan and paclitaxel (Taxol) with filgrastim in patients with advanced non-small cell lung cancer Proc Am Soc Clin Oncol 16 1997 488a [abstract 1755]
31. M.C. Perry, D.C. Ihde, J.E. Herndon, M.L. Grossbard, S.J. Grethein, and J.N. Atkins Paclitaxel-ifosfamide or navelbine-ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532 Lung Cancer 28 2000 63 68
32. P. Comella, and Southern Italy Cooperative Oncology Group Phase III trial of cisplatin/gemcitabine with or without vinorelbine or paclitaxel in advanced non-small cell lung cancer Semin Oncol 28 2001 7 10
33. F.A. Greco, J.R. Gray Jr., D.S. Thompson, H.A. Burris III, J.B. Erland, and J.H. Barton Jr. Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a Minnie Pearl cancer research network trial Cancer 95 2002 1279 1285
34. S.K. Williamson, J.J. Crowley, P.N. Lara, R.W. Tucker, J. McCoy, and D.H.M. Lau S0003: paclitaxel/carboplatin (PC) v PC + tirapazamine (PCT) in advanced non-small cell lung cancer (NSCLC). A phase III southwest oncology group (SWOG) trial Proc Am Soc Clin Oncol 22 2003 622 [abstract 2502]
35. Williamson SK, Crowley JJ, Lara PN, Tucker R, McCoy J, Lau D, et al. S0003: paclitaxel/carboplatin (PC) v PC + tirapazamine in advanced non-small cell lung cancer: a SWOG phase III trial [Internet slide presentation]. ASCO.org Virtual Meeting, 2003 [cited 3 December 2003]. Available from: http://www.asco.org/ac/1,1003,_12-002511-00_18-0023-00_19-003151,00.asp.
36. M.J. Edelman, J.I. Clark, K. Chansky, K. Albain, N. Bhoopalam, and G.R. Weiss Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel Clin Cancer Res 10 2004 5022 5026
37. P. Kosmidis, N. Mylonakis, D. Skarlos, E. Samantas, M. Dimopoulos, and C. Papadimitriou Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial Ann Oncol 11 2000 799 805
38. M.A. Socinski, M.J. Schell, A. Peterman, K. Bakri, S. Yates, and R. Gitten Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer J Clin Oncol 20 2002 1335 1343
39. C.P. Belani, J. Barstis, M.C. Perry, R.V. La Rocca, S.R. Nattam, and D. Rinaldi Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation J Clin Oncol 21 2003 2933 2939
40. K. Roszkowski, A. Pluzanska, M. Krzakowski, A.P. Smith, E. Saigi, and U. Aasebo A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC) Lung Cancer 27 2000 145 157
41. L.R. Pilz, G. Koschel, J. Mezger, K. Schott, W. Spengler, and C. Manegold Quality of life assessment and final results of a randomised phase II study with single-agent gemcitabine and docetaxel given sequentially every 3 weeks show effective treatment in advanced NSCLC Eur J Cancer Suppl 1 2003 S233 [abstract 774]
42. V. Georgoulias, A. Ardavanis, A. Agelidou, M. Agelidou, V. Chandrinos, and E. Tsaroucha Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial J Clin Oncol 22 2004 2602 2609
43. N.V. Jensen, O. Hansen, A.B. Jensen, and C. Rose Carboplatin versus carboplatin plus docetaxel in first line treatment of advanced non-small cell lung cancer (NSCLC). Quality of life, costs and health resources Proc Am Soc Clin Oncol 21 2002 322a [abstract 1285]
44. F. Fossella, J.R. Pereira, J. von Pawel, A. Pluzanska, V. Gorbounova, and E. Kaukel Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group J Clin Oncol 21 2003 3016 3024
45. J.E. Rubio, and G. Sahagun A randomised phase III trial comparing docetaxel + carboplatin (DCP) vs vinorelbine + carboplatin (VCP) in non small cell lung cancer (NSCLC) stage III and IV Proc Am Soc Clin Oncol 22 2003 703 [abstract 2827]
46. K. Kubota, K. Watanabe, H. Kunitoh, K. Noda, Y. Ichinose, and N. Katakami Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese taxotere lung cancer study group J Clin Oncol 22 2004 254 261
47. Lorigan P, Booton R, Ashcroft L, O'Byrne K, Anderson H, Nicolson M, et al. Randomised phase III trial of docetaxel/carboplatin vs MIC/MVP chemotherapy in advanced non-small cell lung cancer (NSCLC) - final results of a British thoracic oncology group (BTOG) trial. J Clin Oncol ASCO Annu Meeting Proc (Post-Meeting Edition) 2004;22(July 15 Suppl. 14S):A7066 [abstract].
48. J.Y. Douillard, R. Gervais, G. Dabouis, A. Le Groumellec, M. D'arlhac, and D. Spaeth Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study Ann Oncol 16 1 2005 81 89
49. V. Georgoulias, E. Papadakis, A. Alexopoulos, X. Tsiafaki, A. Rapti, and M. Veslemes Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial Lancet 357 2001 1478 1484
50. Y. Takiguchi, N. Katakami, K. Yoshimori, H. Isobe, A. Bessho, and A. Yoshimura Docetaxel in combination with either cisplatin (DC) or gemcitabine (DG) in unresectable non-small cell lung carcinoma (NSCLC): a randomized phase II study by the Japan lung cancer cooperative clinical study group Ann Oncol 15 Suppl. 3 2004 iii168 [A635PD, abstract]
51. N. Yamamoto, M. Fukuoka, S.I. Negoro, K. Nakagawa, H. Saito, and K. Matsui Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a west Japan thoracic oncology group study (WJTOG9803) Br J Cancer 90 2004 87 92
52. C.M. Rocha Lima, N.A. Rizvi, C. Zhang, J.E. Herndon, J. Crawford, and R. Govindan Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC Ann Oncol 15 2004 410 418
53. V. Georgoulias, A. Ardavanis, X. Tsiafaki, A. Agelidou, P. Mixalopoulou, and O. Anagnostopoulou Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial J Clin Oncol 23 2005 2937 2945
54. J.L. Pujol, J.L. Breton, R. Gervais, P. Rebattu, A. Depierre, and J.F. Morere Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin Ann Oncol 16 2005 602 610
55. M. Perol, H. Lena, P. Thomas, G. Robinet, P. Fournel, and E. Coste Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study Ann Oncol 13 2002 742 747
56. A.Y. Chang, K. Kim, J. Glick, T. Anderson, D. Karp, and D. Johnson Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the eastern cooperative oncology group results J Natl Cancer Inst 85 1993 388 394
57. A. Clegg, D.A. Scott, P. Hewitson, M. Sidhu, and N. Waugh Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review Thorax 57 2002 20 28
58. R.M. Valori Bias and confounders D.P.B. McGovern R.M. Valori W.S.M. Summerskill M. Levi Key topics in evidence-based medicine 2001 BIOS Scientific Publishers Limited Oxford 101 104
59. K.F. Schulz, and D.A. Grimes Allocation concealment in randomised trials: defending against deciphering Lancet 359 2002 614 618
60. C. Gridelli, F. Perrone, C. Gallo, S. Cigolari, A. Rossi, and F. Piantedosi Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial J Natl Cancer Inst 95 2003 362 372
61. P. Comella, G. Frasci, N. Panza, L. Manzione, V. Lorusso, and G. Di Rienzo Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the southern Italy cooperative oncology group J Clin Oncol 17 1999 1526 1534
62. P. Comella, G. Frasci, N. Panza, L. Manzione, G. De Cataldis, and R. Cioffi Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the southern Italy cooperative oncology group J Clin Oncol 18 2000 1451 1457
63. A.J. Wozniak, J.J. Crowley, S.P. Balcerzak, G.R. Weiss, C.H. Spiridonidis, and L.H. Baker Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a southwest oncology group study J Clin Oncol 16 1998 2459 2465
64. Banerjee S, Moher D, Stewart DJ. Treatment of inoperable advanced non-small-cell lung cancer: regimens with or without taxane. CCOHTA website, 2002 [cited 10 August 2004]. Available from: http://www.ccohta.ca/entry_e.html.
65. F.V. Fossella, R. DeVore, R.N. Kerr, J. Crawford, R.R. Natale, and F. Dunphy Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group J Clin Oncol 18 2000 2354 2362
66. R. Gervais, J. Douillard, H. Lacroix, A. Le Groumellec, D. Spaeth, and M. D'arlhac Preliminary results of a randomized study on first and second line chemotherapy strategy in stage IV non-small cell lung cancer (NSCLC), assessing docetaxel (D) and cisplatin (C) until progressive disease (Pd) then vinorelbine (V) versus V-C until Pd then D Proc Am Soc Clin Oncol 19 2000 498 [abstract 1950]
67. G. D'Addario, M. Pintilie, N.B. Leighl, R. Feld, T. Cerny, and F.A. Shepherd Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature J Clin Oncol 23 2005 2926 2936
68. C. Gridelli, C. Gallo, M. Di Maio, E. Barletta, A. Illiano, and P. Maione A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study Br J Cancer 91 2004 1996 2004
69. D. Logan, S. Laurie, B.R. Markman, M. McNeil, M. Vincent, and W.K. Evans The role of single-agent docetaxel as second-line treatment for advanced non-small-cell lung cancer Curr Oncol 8 2001 50 59